Log In / Register
Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C completed
31 October, 2019
Cyclo Therapeutics, Inc. announced that it has completed patient enrollment in its Phase I trial to evaluate the safety and tolerability of Trappsol
Cyclo™ administered intravenously to Niemann-Pick Disease Type C (NPC) patients.
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., is a biotechnology company that develops cyclodextrin-based products for the treatment of NPC disease.
BACK TO NEWS